Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohns Disease Patients with Loss of Response to Adalimumab Especially in Cases without Previous Infliximab Treatment

摘要

Background/AimsAdalimumab dose escalation is one of the most important options in refractory Crohn's disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in Crohn's disease patients with loss of response to adalimumab, since there are few reports of adalimumab dose escalation, especially in East Asia.